Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 6/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.77 |
| ▸ | GLA | P06280 | 3/20 | 0.77 |
| ▸ | GAA | P10253 | 3/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.77 |
| ▸ | ESR1 | P03372 | 5/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | CASP1 | P29466 | 2/20 | 0.58 |
| ▸ | CASP7 | P55210 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NQO1 | P15559 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648321 | 0.88 | HSD17B3 (0.70) | HSD17B3KDM4EGLAGAANPSR1 | |
| SCHEMBL5647264 | 0.87 | HSD17B3 (0.77) | HSD17B3KDM4EGLAGAANPSR1 | |
| SCHEMBL1590671 | 0.87 | HSD17B3 (0.77) | HSD17B3KDM4EGLAGAANPSR1 | |
| SCHEMBL971942 | 0.87 | KDM4E (1.00) | HSD17B3KDM4EGLAGAANPSR1 | |
| SCHEMBL12204224 | 0.86 | HSD17B3 (0.68) | HSD17B3KDM4EGLAGAANPSR1 | |
| SCHEMBL15931615 | 0.86 | HSD17B3 (0.68) | HSD17B3KDM4EGLAGAANPSR1 | |
| SCHEMBL14317882 | 0.86 | HSD17B3 (0.76) | HSD17B3KDM4EGLAGAANPSR1 | |
| SCHEMBL28668975 | 0.85 | HSD17B3 (0.73) | HSD17B3KDM4EGLAGAANPSR1 | |
| SCHEMBL13391475 | 0.85 | HSD17B3 (0.73) | HSD17B3KDM4EGLAGAANPSR1 | |
| SCHEMBL960393 | 0.83 | HSD17B3 (0.70) | HSD17B3KDM4EGLAGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| EP-2720695-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NoNO Inc. (CA) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | TRPM7, TRPM8, TRPM5 | HSD17B3 3885/4885KDM4E 4656/4885GLA 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.